JP2004511527A - ワクチン - Google Patents

ワクチン Download PDF

Info

Publication number
JP2004511527A
JP2004511527A JP2002535687A JP2002535687A JP2004511527A JP 2004511527 A JP2004511527 A JP 2004511527A JP 2002535687 A JP2002535687 A JP 2002535687A JP 2002535687 A JP2002535687 A JP 2002535687A JP 2004511527 A JP2004511527 A JP 2004511527A
Authority
JP
Japan
Prior art keywords
neu
prostase
antigen
cpg
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002535687A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004511527A5 (cg-RX-API-DMAC10.html
Inventor
ガルコン，ナタリー
ジェラール，カトリーヌ，マリー，ギースレーヌ
ステファンヌ，ジャン
Original Assignee
グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/690,921 external-priority patent/US6544518B1/en
Priority claimed from GB0025573A external-priority patent/GB0025573D0/en
Priority claimed from GB0025574A external-priority patent/GB0025574D0/en
Application filed by グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム filed Critical グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム
Publication of JP2004511527A publication Critical patent/JP2004511527A/ja
Publication of JP2004511527A5 publication Critical patent/JP2004511527A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2002535687A 2000-10-18 2001-10-16 ワクチン Pending JP2004511527A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/690,921 US6544518B1 (en) 1999-04-19 2000-10-18 Vaccines
GB0025573A GB0025573D0 (en) 2000-10-18 2000-10-18 Vaccine
GB0025574A GB0025574D0 (en) 2000-10-18 2000-10-18 Vaccine
PCT/EP2001/011984 WO2002032450A2 (en) 2000-10-18 2001-10-16 Vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008126888A Division JP2008285487A (ja) 2000-10-18 2008-05-14 ワクチン

Publications (2)

Publication Number Publication Date
JP2004511527A true JP2004511527A (ja) 2004-04-15
JP2004511527A5 JP2004511527A5 (cg-RX-API-DMAC10.html) 2005-12-22

Family

ID=27255945

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002535687A Pending JP2004511527A (ja) 2000-10-18 2001-10-16 ワクチン

Country Status (18)

Country Link
EP (2) EP1326638B9 (cg-RX-API-DMAC10.html)
JP (1) JP2004511527A (cg-RX-API-DMAC10.html)
KR (1) KR100860893B1 (cg-RX-API-DMAC10.html)
CN (1) CN100548373C (cg-RX-API-DMAC10.html)
AU (2) AU2002244337B2 (cg-RX-API-DMAC10.html)
BR (1) BR0114786A (cg-RX-API-DMAC10.html)
CA (1) CA2425358C (cg-RX-API-DMAC10.html)
CZ (1) CZ302449B6 (cg-RX-API-DMAC10.html)
DK (1) DK1326638T3 (cg-RX-API-DMAC10.html)
ES (1) ES2295229T3 (cg-RX-API-DMAC10.html)
HU (1) HU229642B1 (cg-RX-API-DMAC10.html)
IL (1) IL155282A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA03003408A (cg-RX-API-DMAC10.html)
NO (1) NO335919B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ525320A (cg-RX-API-DMAC10.html)
PL (1) PL208755B1 (cg-RX-API-DMAC10.html)
SI (1) SI1326638T1 (cg-RX-API-DMAC10.html)
WO (1) WO2002032450A2 (cg-RX-API-DMAC10.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008506789A (ja) * 2004-07-18 2008-03-06 シーエスエル、リミテッド インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
JP2008531637A (ja) * 2005-03-03 2008-08-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 水疱−帯状疱疹ウイルスワクチン
JP2016503029A (ja) * 2012-12-13 2016-02-01 アデュロ バイオテック，インコーポレイテッド 明確な立体化学を有する環状プリンジヌクレオチドを含む組成物ならびにそれらの調製および使用方法
JP2016534977A (ja) * 2013-09-19 2016-11-10 ゾエティス・サービシーズ・エルエルシー 油性アジュバント
US10131686B2 (en) 2013-04-29 2018-11-20 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE315405T1 (de) 1998-08-10 2006-02-15 Antigenics Inc Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
DE60044236D1 (de) 1999-02-17 2010-06-02 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
US20060210555A1 (en) 2001-12-21 2006-09-21 Antigenics, Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
KR100456681B1 (ko) 2002-05-22 2004-11-10 주식회사 대웅 박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
ATE489969T1 (de) * 2002-06-20 2010-12-15 Cytos Biotechnology Ag Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
JP2006501249A (ja) * 2002-08-30 2006-01-12 グラクソ　グループ　リミテッド ワクチン
NZ546275A (en) 2003-10-30 2009-05-31 Coley Pharm Gmbh C-class oligonucleotides analogs with enhanced immunostimulatory potency
EP1812052A1 (en) * 2004-11-02 2007-08-01 Biomedical Research Models, Inc. Methods of cancer treatment/prevention using cancer cell-specific surface antigens
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
WO2007052055A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2468300B1 (en) 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
BRPI0923225A2 (pt) 2008-12-02 2016-10-04 Chiralgen Ltd metodo para sintese de acidos nucleicos modificados no atomo de fosforo
EA023662B1 (ru) 2009-02-10 2016-06-30 Новартис Аг Вакцины против гриппа со сниженным количеством сквалена
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
CN107029223A (zh) 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN107365339A (zh) 2011-07-19 2017-11-21 波涛生命科学有限公司 合成官能化核酸的方法
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
AU2012301664A1 (en) * 2011-08-31 2014-02-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of cancer
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
DK2872147T3 (da) 2012-07-13 2023-02-20 Wave Life Sciences Ltd Fremgangsmåde til fremstilling af kirale oligonukleotider
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
SG11201500243WA (en) * 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
EP2777711A1 (en) * 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
EP3094728B1 (en) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chiral design
AU2020403296B2 (en) 2019-12-13 2025-03-06 Grand Theravac Life Science (Nanjing) Co., Ltd. Immunostimulatory composition and use thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59186921A (ja) * 1982-10-18 1984-10-23 ブロル・モレイン 免疫原性複合物
JPH11504020A (ja) * 1995-04-25 1999-04-06 スミスクライン・ビーチャム・バイオロジカルス （ソシエテ・アノニム） サポニンおよびステロールを含有するワクチン
WO1999040188A2 (en) * 1998-02-05 1999-08-12 Smithkline Beecham Biologicals S.A. Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccinations
WO1999061056A2 (en) * 1998-05-22 1999-12-02 Loeb Health Research Institute At The Ottawa Hospital Methods and products for inducing mucosal immunity
WO2000009159A1 (en) * 1998-08-10 2000-02-24 Aquila Biopharmaceuticals, Inc. Compositions of cpg and saponin adjuvants and methods thereof
WO2000044899A1 (en) * 1999-01-29 2000-08-03 Corixa Corporation Her-2/neu fusion proteins
JP2002542203A (ja) * 1999-04-19 2002-12-10 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2397374A1 (en) * 2000-01-13 2001-07-19 Antigenics Inc. Innate immunity-stimulating compositions of cpg and saponin and methods thereof
WO2002069369A2 (en) * 2000-12-08 2002-09-06 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59186921A (ja) * 1982-10-18 1984-10-23 ブロル・モレイン 免疫原性複合物
JPH11504020A (ja) * 1995-04-25 1999-04-06 スミスクライン・ビーチャム・バイオロジカルス （ソシエテ・アノニム） サポニンおよびステロールを含有するワクチン
WO1999040188A2 (en) * 1998-02-05 1999-08-12 Smithkline Beecham Biologicals S.A. Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccinations
WO1999061056A2 (en) * 1998-05-22 1999-12-02 Loeb Health Research Institute At The Ottawa Hospital Methods and products for inducing mucosal immunity
WO2000009159A1 (en) * 1998-08-10 2000-02-24 Aquila Biopharmaceuticals, Inc. Compositions of cpg and saponin adjuvants and methods thereof
WO2000044899A1 (en) * 1999-01-29 2000-08-03 Corixa Corporation Her-2/neu fusion proteins
JP2002542203A (ja) * 1999-04-19 2002-12-10 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008506789A (ja) * 2004-07-18 2008-03-06 シーエスエル、リミテッド インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
JP2008531637A (ja) * 2005-03-03 2008-08-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 水疱−帯状疱疹ウイルスワクチン
JP2016503029A (ja) * 2012-12-13 2016-02-01 アデュロ バイオテック，インコーポレイテッド 明確な立体化学を有する環状プリンジヌクレオチドを含む組成物ならびにそれらの調製および使用方法
JP2018135367A (ja) * 2012-12-13 2018-08-30 アデュロ バイオテック，インコーポレイテッド 明確な立体化学を有する環状プリンジヌクレオチドを含む組成物ならびにそれらの調製および使用方法
US10414789B2 (en) 2012-12-13 2019-09-17 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
US10131686B2 (en) 2013-04-29 2018-11-20 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
US10385091B2 (en) 2013-04-29 2019-08-20 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
US11014956B2 (en) 2013-04-29 2021-05-25 Memorial Sloan Kettering Cancer Center; The Rockefeller Compositions and methods for altering second messenger signaling
JP2016534977A (ja) * 2013-09-19 2016-11-10 ゾエティス・サービシーズ・エルエルシー 油性アジュバント

Also Published As

Publication number Publication date
PL208755B1 (pl) 2011-06-30
HU229642B1 (en) 2014-03-28
NO20031705L (no) 2003-06-14
WO2002032450A2 (en) 2002-04-25
EP1326638A2 (en) 2003-07-16
ES2295229T3 (es) 2008-04-16
NO335919B1 (no) 2015-03-23
CZ20031093A3 (cs) 2003-08-13
BR0114786A (pt) 2003-08-12
CZ302449B6 (cs) 2011-05-25
CA2425358A1 (en) 2002-04-25
MXPA03003408A (es) 2005-06-30
WO2002032450A3 (en) 2002-10-10
AU4433702A (en) 2002-04-29
KR100860893B1 (ko) 2008-09-29
DK1326638T3 (da) 2008-03-25
HUP0402067A3 (en) 2012-09-28
EP1326638B1 (en) 2007-11-28
NO20031705D0 (no) 2003-04-11
HUP0402067A2 (hu) 2005-01-28
AU2002244337B2 (en) 2005-08-11
NZ525320A (en) 2004-10-29
CN1481255A (zh) 2004-03-10
EP1326638B9 (en) 2008-02-20
EP1889630B1 (en) 2011-11-23
CA2425358C (en) 2012-08-21
PL365598A1 (en) 2005-01-10
IL155282A0 (en) 2003-11-23
SI1326638T1 (sl) 2008-04-30
CN100548373C (zh) 2009-10-14
KR20070114230A (ko) 2007-11-29
EP1889630A1 (en) 2008-02-20

Similar Documents

Publication Publication Date Title
KR100860893B1 (ko) 백신
AU2002244337A1 (en) Vaccines
JP2008285487A (ja) ワクチン
US20030161834A1 (en) Vaccines
US20070243196A1 (en) Mage-3 and NY-ESO-1 Based Polyvalent Vaccine for Cancer Immunotherapy
PL203894B1 (pl) Kompozycja szczepionki i sposób jej wytwarzania, oraz zastosowanie
ZA200302885B (en) Vaccines.
HK1057992B (en) Vaccines against cancers
HK1117729B (en) Vaccines comprising mage antigen linked to protein d fragment
HK1147673B (en) Tumour vaccines
KR20070022064A (ko) 암 면역치료를 위한 ｍａｇｅ-3 및 ｎｙ-ｅｓｏ-1 기재다가 백신

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080514

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20080703

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20080725